Neumora Therapeutics

Neumora Therapeutics

NMRA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -83.1% in FY2025

Paul L. Berns is the CEO of Neumora Therapeutics and was paid $4.6M in FY2025 (Dec), down 47%.

Pay$100 in the stock at the end of FY23 → $10
CEO pay is from each Neumora Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Joshua Pinto, Ph.D.FY2025
  2. 2Paul L. BernsFY2025
  3. 3Bill Aurora, Pharm.D.FY2025
  4. 4Henry O. GosebruchFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Neumora Therapeutics paid its 4 named executives $15.9M in total in FY2025 (Dec). CEO Paul L. Berns was paid $4.6M of that.

Name
Joshua Pinto, Ph.D.PresidentNot disclosed
Paul L. BernsChief Executive Officer
Bill Aurora, Pharm.D.Chief Strategy Officer
Henry O. GosebruchFormer President and Chief Executive Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Neumora Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • David PiacquadDirector · 2 yr on the boardIndependentAudit—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Neumora Therapeutics Chief Strategy Officer pay fell 37% to $3.3M. The stock fell 83% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Neumora Therapeutics CEO pay fell 47% to $4.6M. The stock fell 83% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Neumora Therapeutics President pay rose 46% to $6.7M. The stock fell 83% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Neumora Therapeutics President pay fell 72% to $1.3M. The stock fell 83% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Neumora Therapeutics Chief Strategy Officer pay rose 64% to $5.2M. The stock fell 38% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Neumora Therapeutics President pay fell 78% to $4.8M. The stock fell 38% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Neumora Therapeutics CEO pay rose 225% to $8.6M in FY2023 (Dec).
    DEF 14A
  8. Board
    David Piacquad joined the board of Neumora Therapeutics. David Piacquad sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 17, 2026FY2025
Annual report10-KMar 30, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 3, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KMar 7, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data